Epigenetic Effects of Intranasal SteroidsEnvironmental Exposure
Investigational drug(s) / intervention(s)
Budesonide NasalPlacebo
Budesonide Nasal: budesonide 64 mcg/spray; 2 sprays each nostril once daily on days as indicated in the timeline
Placebo: 2 sprays each nostril daily on days as indicated in the timeline
Study summary
Around 40% of the world's population is now impacted by allergic disease and this figure continues to rise. It is now understood that allergic disease arises from complex interactions between genetic and environmental factors. Exposure to allergens such as dust mites and pollen, as well as air pollutants such as diesel exhaust particulates, can alter the ability of critical genes to be expressed appropriately, a process known as epigenetic modification. The epigenetic modifications induced by allergens and pollutants appears to be reversible, thus providing a mechanism by which allergic disease can be treated. Budesonide (Rhinocort®) is a corticosteroid nasal spray commonly used to treat allergy symptoms. While the anti- inflammatory and other pharmacological aspects of budesonide are well understood, recent studies have suggested that budesonide may also work by reversing the epigenetic modifications caused by allergen exposure, although this has not been examined in the context of real-world exposures in humans.
This study aims to harness the power of epigenetic analysis to determine whether the epigenetic landscape in patients suffering from allergic disease can be modified by the administration of budesonide. It will fill critical gaps in understanding of epigenetic effects and provide information to examine the connection between environmental impacts and treatment effects. The research will expand the mechanistic understanding of the therapeutic effects of budesonide for relief of nasal rhinitis symptoms and may reveal new mechanisms that could improve treatment of allergies or pollution exposure, or serve as a tool for evaluating future therapies. If this venture is successful, it will serve as a model for studying and optimizing the epigenetic effects of other treatments and other diseases.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
* Healthy men and women aged 18 - 65 years. (Female subjects must be postmenopausal, surgically sterile or using medically accepted contraceptive means, as judged by the investigator).
* Asymptomatic subjects (not experiencing rhinitis symptoms at the time of screening).
* A clinical diagnosis of allergic rhinitis (dust mite, grass mix or tree mix) for at least the previous two years.
* Subjects with a need of treatment for their nasal symptoms during the pollen season of such severity that it required pharmacological therapy each year for the last two consecutive years.
* Willingness to participate as indicated by a signed informed consent. Signed consent must be obtained from the subject prior to start of any study-related procedures.
* Availability and ability for all planned site visits
* A nasal allergen challenge resulting in at least five sneezes and/or a recorded score of \>2 in either nasal obstruction or runny nose
Exclusion Criteria:
* Subjects with confirmed hypersensitivity to budesonide.
* Subjects with previous or current respiratory- cardiovascular-, renal-, liver-, endocrinological or other diseases or conditions which may influence the subject's participation in the study or the result hereof, as judged by the investigator.
* Subjects with a planned hospitalization or planned blood-donation during the study.
* Women who are pregnant or nursing.
* Diseases or conditions which might interfere with the evaluation of efficacy and safety:
* Subjects with structural abnormalities of the nose (e.g. septal deviation, nasal polyps) or other diseases (infectious rhinitis, sinusitis, rhinitis medicamentosa and atrophic or non- allergic rhinitis) which could cause significant nasal obstruction or other symptoms which could have any significant influence on the investigated disease as judged by the investigator.
* History of asthma.
* PAR (with an exception, see inclusion criterion 3).
* Subjects allergic to other allergens occurring during the study period.
* Systemic corticosteroid use within 2 months, topical corticosteroid use within 2 weeks, antihistamine use within 1 week, leukotriene antagonist use within one week or immunotherapy within 2 years of baseline visit (or stop at screening)
* Upper respiratory infection within 2 weeks of baseline visit
* Use of tobacco within 1 year of baseline
* Chronic medical condition that could interfere with evaluation of rhinitis endpoints (e.g. allergic skin conditions, active infections, asthma, etc.)
Primary outcome measure(s)
Budesonide affect on allergic rhinitis plus allergen (48 hrs) — Baseline vs 48 hours Change in DNA methylation in the budesonide group compared with placebo.
DNA methylation measurement tool:
Illumina Infinium MethylationEPIC BeadChip (interrogates 866,895 CpG sites across the human genome)
Unit of Measure:
For each targeted CpG site, the intensity of fluorescence will be translated into a level of DNA methylation which is either represented as a β value, a number between 0 and 1 (0 = no methylated, 1 = fully methylated) for visualization and interpretation, or a logit-transformed β value "M value" for statistical analysis.
Trial sites (1)
Facility
City
Region
Status
University of British Columbia
Vancouver
British Columbia
More University of British Columbia trials in Canada
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.